ABSTRACT 1SI-labeled recombinant human interleukin 3 (IL-3) bound, at 40C, to a single class of hig-affinity receptors on human eosinophils with an apparent dissociation constant (Kd) of 470 pM, but it did not bind to human neutrophils. 12I-labeled recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) also bound to a single class of high-affinity receptors on eosinophils with an apparent Kd of 44 pM and on neutrophils with an apparent Kd of 70 pM. These binding characteristics were conssent with the biological activities ofIL-3 and GM-CSF on eosinophils and with the lack of stimulation of neutrophil function by IL-3. Specificity studies under conditions shown to prevent receptor internalization showed that the binding of '2I-labeled IL-3 to eosinophils was partially inhibited by GM-CSF but not by other cytokines. Reciprocal experiments with 12I-labeled GM-CSF showed that IL-3 but not other cytokines partially inhibited binding to einophils. In contrast, the binding of '25I-hbeled GM-CSF to neutrophils was not inhibited by IL-3 or other cytokines tested. Quantitative inhibition binding experiments on eosinophils showed that the reciprocal inhibition between IL-3 and GM-CSF was not complete up to a concentration of heterologous ligand of 100 nM. These results show that (i) IL-3 binds to eosinophils but not neutrophils and (ii) IL-3 and GM-CSF specifically interact on the surface of eosinophils, providing a possible mechanism for the overlapping activities of IL-3 and GM-CSF on these cells.
Eosinophils are specialized hemopoietic cells found in blood and other tissues whose numbers and functional status rise in pathological situations such as parasitic infections, allergic reactions, and certain neoplasias (1) (2) (3) (4) . The production and function of eosinophils is controlled, at least in vitro, by a group of hemopoietic growth factors termed interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-5 (5) (6) (7) (8) (9) (10) (11) . Recent experiments showing increased levels of eosinophils after administration of IL-3 and GM-CSF suggest that these molecules also work in vivo (12, 13) .
The existence of three hemopoietic growth factors with overlapping activities on eosinophils is puzzling and may reflect similarities in the structure of these molecules or in their mechanism of eosinophil stimulation. Computer analysis of the amino acid sequence of these molecules revealed that mouse IL-3 and GM-CSF have similarities at their N terminus (14) . In humans, IL-3 and IL-5 have sequence similarity in the C terminus (5) ; this similarity was also noted in comparisons including GM-CSF, . It is also noteworthy that the genes coding for IL-3, GM-CSF, and IL-5 have a similar genomal organization (16) and are closely linked on the long arm of chromosome 5 (17, 18) . In particular, the IL-3 and GM-CSF genes are only 9 kilobases apart, a finding that led to the speculation that these genes may have arisen from a common ancestral gene (19) .
Despite the similarities of IL-3 and GM-CSF in the genomal organization and localization of their genes and in their primary structure, it is not known whether this apparent relatedness is manifested at the level of binding of these growth factors to the surface ofeosinophils. In this report, we studied the interaction of radiolabeled IL-3 and GM-CSF with eosinophils at 40C and the specificity of this interaction in relation to other eosinophil-activating and nonactivating cytokines. Our results show that IL-3 and GM-CSF bind to high-affinity receptors on the surface of human eosinophils and that their binding is inhibited by each other but not by other cytokines. This suggests an intimate interaction of IL-3 and GM-CSF on the eosinophil surface, which may explain their overlapping activities on these cells. In addition, we show that this interaction is absent on human neutrophils.
MATERIALS AND METHODS
Purification of Human Eosinophils and Neutrophils. Eosinophils were obtained from the peripheral blood of slightly hypereosinophilic patients after dextran sedimentation and centrifugation on a hypertonic gradient of metrizamide (Nyegaard, Oslo) as described (20) . Cell purity was always >90%. In one case, eosinophils were obtained from the pleural fluid of a patient with eosinophilic pleural effusion after density gradient centrifugation on Lymphoprep (Nyegaard). This preparation contained 99% eosinophils. Neutrophils were purified from normal volunteers by centrifugation on a hypertonic gradient of metrizamide as described (20) and were always >97% pure, with no contaminating eosinophils. The cells were resuspended in RPMI 1640 medium (pH 7.4) supplemented with 20 mM Hepes, 2% (vol/vol) fetal calf serum, and antibiotics.
Cytokines. Recombinant human (rh) IL-3 and rhIL-6 produced in Escherichia coli and rhGM-CSF and recombinant human macrophage colony-stimulating factor (rhM-CSF) produced in COS cells were obtained from Genetics Institute (Cambridge, MA). rhIL-4 (in binding medium) and rhIL-5 produced in yeast were obtained from Immunex Corporation (Seattle). Recombinant human tumor necrosis factor a (rhTNF-a) produced in E. coli was obtained from Genentech, and recombinant human granulocyte colony-stimulating factor (rhG-CSF) produced in E. coli was obtained from L. Souza (Amgen, Thousand Oaks, CA). All cytokines were Abbreviations: IL-n, interleukin n; GM-CSF, granulocytemacrophage colony-stimulating factor; TNF-a, tumor necrosis factor a; ADCC, antibody-dependent cell-mediated cytotoxicity; rh, recombinant human; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. >99o pure as specified by the suppliers. For binding studies, an rhIL-3 produced in yeast and modified by the addition of a tyrosine-containing N-terminal octapeptide was used. This rhIL-3 has unaltered biological activity (21) .
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assay. This assay was performed with 51Cr-labeled P815 cells coupled to trinitrophenyl as targets as previously described (22) . The percent cytotoxicity was determined according to the following formula: 100 x (test -control)/(total -control), where total was the 51Cr released by the addition of 2% (wt/vol) Triton X-100 (Ajax Chemicals, Auburn, New South Wales, Australia) and control was the amount of label released by P815 cells alone. Results shown are the mean of triplicate determination, with the SD always <15% of the mean.
Radioiodination of Cytokines. IL-3 and GM-CSF were radioiodinated to high specific radioactivity by an iodine monochloride method (23 (24) . Cell suspensions were cooled on ice, overlayed onto 0.2 ml of fetal calf serum at 4°C, and centrifuged for 30 sec at maximum speed in a Beckman Microfuge 12. The visible cell pellet was removed by cutting, and the radioactivity in the pellet was determined in a Packard Auto-Gamma 5650. Nonspecific binding was determined by incubation in the presence of a 100-fold excess of unlabeled cytokine. Specific binding was calculated by subtracting nonspecific binding from total binding. Free radioligand was the difference between total and specifically bound radioactivity.
To determine the amount ofreceptor-ligand internalization under these conditions, acid-resistant radioactivity was measured at the conclusion of the assay (25) . Briefly, cell suspensions were centrifuged through 0.5 ml of ice-cold fetal calf serum; the cell pellet was resuspended in binding medium and divided into two identical samples. Each aliquot was diluted in two volumes of 0.5 M acetic acid/0.5 M NaCl (pH 2.0) or binding medium (pH 7.4) for 5 min on ice and then centrifuged through fetal calf serum as described. Dissociable radioactivity was defined as the difference between total and acid-resistant specific radioactivity bound.
Binding data were analyzed by the EBDA and LIGAND computer programs (Elsevier-BIOSOFT, Cambridge, England) (26) . For Scatchard analysis (27), free radioactivity was corrected for maximal binding capacity (28, 29) , and the specific radioactivity of the radioligand was determined by self-displacement analysis (30) (Fig. 1) . Titration experiments showed that, although IL-3 and GM-CSF stimulated similar levels of cytotoxicity at high concentrations, GM-CSF was more potent on a molar basis. Thus the concentrations required for 50%o stimulation of eosinophil ADCC were 1-10 pM for GM-CSF and 10-100 pM for IL-3 (range of three different experiments).
Binding Characteristics of IL-3 and GM-CSF on Eosino- Similarly no specific 1251-IL-3 binding was detected on the promyelocytic leukemic cell line HL-60 (data not shown). Eosinophils were also found to bind 125I-GM-CSF over a range of concentrations, with saturation achieved at a radioligand concentration of approximately 200 pM (Fig. 2C) . Scatchard analysis demonstrated the presence of about 840 receptors per cell and an apparent Kd of 53 pM (Fig. 2D) . A second experiment with eosinophils (99% pure) and eight different concentrations of radioligand indicated the presence of 520 receptors per cell and an approximate Kd of 36 pM. In parallel experiments with neutrophils (96% pure), 1251_ Under these experimental conditions, most of the radioactivity remained surface bound and very little was internalized as revealed by acid elution experiments. In a typical experiment with eosinophils incubated with 125I-GM-CSF for 16 hr at 40C, the specific cpm obtained at pH 7.4 was 2238 ± 50 (mean ± SEM) and at pH 2.0 was 291 ± 36, indicating that about 87% of the cytokine was dissociable (i.e., surface bound).
Specificity of IL-3 and GM-CSF Binding. To determine whether the binding of IL-3 and GM-CSF to human eosinophils was specific for these growth factors, competition binding experiments with other eosinophil-stimulating and nonstimulating cytokines were performed. In these experiments, eosinophils were incubated with a nonsaturating concentration of radiolabeled IL-3 or GM-CSF based on the respective saturation binding curves (see Fig. 2 ) and different cytokines at >100-fold mass -excess. We found that the binding of 125I-IL-3 to eosinophils (99%o pure) was inhibited not only by unlabeled IL-3 but also partially by GM-CSF (Fig. 3) . IL-4, IL-5, IL-6, TNF-a, G-CSF, and M-CSF did not inhibit binding at this concentration (Fig. 3) . Conversely, the specific binding of 125I-GM-CSF to the eosinophils from the same donor could be inhibited partially by IL-3 but not by other cytokines (Fig. 3) . In contrast to eosinophils, the binding of 125I-GM-CSF to neutrophils (98% pure) was not inhibited by levels of this inhibition varied between different individuals, the possibility that complete inhibition could be achieved by using optimal concentrations of heterologous competitor was examined by carrying out quantitative inhibition experiments. We found that 125I-IL-3 binding to eosinophils could be inhibited by increasing concentrations of GM-CSF, although this inhibition did not reach the levels obtained with unlabeled IL-3 up to a concentration of 100 nM (equivalent to 1500-fold excess) (Fig. 4) . The converse was also observed, with increasing concentrations of unlabeled IL-3 inhibiting the binding of 125I-GM-CSF. In this case, the heterologous inhibition was greater although not complete.
DISCUSSION
The results presented here show that IL-3 and GM-CSF specifically interact on the surface of eosinophils partially inhibiting the binding of each other. These findings suggest a possible mechanism for the overlapping activities of IL-3 and GM-CSF in eosinophilopoiesis and the stimulation of function of mature eosinophils. These results also show that eosino- The binding of IL-3 and GM-CSF to eosinophils is consistent with the ability of these growth factors to stimulate the function of these cells and suggests that IL-3 and GM-CSF receptors are expressed on the eosinophil lineage throughout differentiation. In contrast, we found that, although IL-3 stimulates the neutrophil myeloid series (31) , no detectable receptors were found on mature neutrophils, a result that correlates with the lack of stimulation of neutrophil function by IL-3 (31). Neutrophils, however, bound GM-CSF, in agreement with previous reports (32, 33) .
IL-3 and GM-CSF bound to a small number of high-affinity receptors (300-1000) on eosinophils, with the Kd of these interactions within the range of concentrations required to stimulate their function. Interestingly, IL-3 bound to eosinophils with a Kd approximately 10 times that of GM-CSF, a result that correlates with the requirement for higher concentrations of IL-3 than GM-CSF to stimulate eosinophil function. The apparent Kd of GM-CSF binding to eosinophils (40-60 pM) was similar to that of neutrophils (70 pM). The binding of radiolabeled IL-3 to eosinophils was found to be inhibited not only by unlabeled IL-3 but also by GM-CSF, and the converse was also seen. This was surprising in view of the demonstration of specific receptors for these factors in the mouse system in experiments carried out at 40C, although inhibition of binding occurred at 3rC, a phenomenon termed down-modulation (34 (36, 37) , this is not the case in neutrophils. In addition, while eosinophils show a single class of high-affinity receptors for IL-3 and for GM-CSF, monocytes express high-affinity as well as lowaffinity receptors for each cytokine (37) .
125I-GM-CSF
The precise mechanism ofthe IL-3 and GM-CSF reciprocal inhibition on eosinophils is not yet understood. It is not clear, for example, why IL-3, which has an apparent Kd higher than that of GM-CSF on eosinophils, appears to be the better competitor at low concentrations. Similarly, it remains to be elucidated whether the IL-3 and GM-CSF reciprocal inhibition is due to a common binding protein or to a specific association of receptors for these cytokines on the eosinophil membrane. A precedent for the former can be found in a binding protein of 70,000-74,000 Da present in the GH3 pituitary cells capable of binding activin, inhibin, and transforming growth factor P (38 
